Polsinelli Podcasts - FDA Denies Amgen Citizen Petition in Biosimilar Dispute
Despite increasingly aggressive rhetoric from the agencies, 2022 was largely characterized as “business as usual” in the antitrust world. In contrast, 2023 featured a significant step up in enforcement activity, including...more